- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dr Reddy's Russia Arm Slapped Rs 2.45 Cr VAT Penalty

New Delhi: Drug major Dr. Reddy's Laboratories Limited's step-down wholly owned subsidiary, Dr. Reddy's Laboratories LLC, Russia, has received a tax audit decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia, resulting in a Value Added Tax (VAT) levy and a monetary penalty of Ruble 20.09 million (approximately Rs 24.50 million).
In a regulatory disclosure, the company stated that the tax audit decision was received on January 23, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
According to the disclosure, the Russian tax authority has reclassified certain marketing services as taxable services, which led to the levy of VAT on the subsidiary. Following this reclassification, the authority quantified a penalty of Ruble 20.09 million, equivalent to ₹24.50 million.
Dr Reddy’s clarified that, based on its internal evaluation, the tax audit order is not expected to have any material impact on the company’s financials, operations, or other business activities, despite the penalty imposed.
The pharmaceutical company further stated that it will evaluate the matter and file the necessary reply or response with the concerned authority in connection with the tax audit decision.
Also Read: Dr Reddy's Denosumab Biosimilar AVT03 Faces USFDA Setback After Plant Inspection
M. Pharm (Pharmaceutics)
Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

